日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma

KEYNOTE-585研究中生存期的替代终点:新辅助/辅助帕博利珠单抗联合化疗与安慰剂联合化疗治疗胃癌或胃食管交界处腺癌的比较

Shitara, K; Bang, Y-J; Wyrwicz, L S; Rha, S Y; Oshima, T; Pietrantonio, F; Park, Y-K; Lonardi, S; Yañez, P; Yen, C-J; Metges, J-P; Garrido, M; Moehler, M; Pelles-Avraham, S; Yong, W P; Spallanzani, A; Jensen, E; Krishnan, R; Shih, C-S; Al-Batran, S-E

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

一项针对既往接受过治疗的晚期不可切除转移性结直肠癌患者的 II 期随机研究,评估了 magrolimab 联合贝伐单抗-FOLFIRI 方案的疗效。

Fakih, M; Gill, S; Sampat, K; Chan, D L; Fisher, G; Cruz-Correa, M; Lenz, H-J; Garcia-Alfonso, P; Forget, F; Lonardi, S; Krauss, J; Chen, E; Cubillo Gracian, A; Liu, Y; van Buuren, N; Shao, J; Dong, M; Chen, A; Tejani, M; Hecht, J R

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer

DESTINY-Gastric05 III期临床试验,评估一线曲妥珠单抗德鲁替康、化疗和帕博利珠单抗治疗HER2阳性胃癌或胃食管交界处癌的疗效。

Janjigian, Y Y; Smyth, E; Shen, L; Lee, J; Hoff, P M; Lonardi, S; Barrios, D; Kobayashi, K; Okuda, Y; Kamio, T; Shitara, K

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study

HER-2基因改变作为接受FOLFIRI联合西妥昔单抗治疗的转移性结直肠癌患者的生物标志物:CAPRI-2 GOIM研究结果

Ciardiello, D; Boscolo Bielo, L; Napolitano, S; Martinelli, E; Troiani, T; Cioli, E; Latiano, T P; Maiello, E; Parente, P; Avallone, A; De Stefano, A; Bordonaro, R; Russo, A E; Lotesoriere, C; Vallarelli, S; Pisconti, S; Nisi, C; Tamburini, E; Viola, M G; Lonardi, S; Cremolini, C; Iacono, D; Tagliaferri, P; Pietrantonio, F; Tortora, G; Rosati, G; Zampino, M G; Curigliano, G; Febbraro, A; Normanno, N; De Vita, F; Fazio, N; Ciardiello, F; Martini, G

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study

在MMR功能正常的转移性结直肠癌患者中,肝转移并不能预测一线FOLFOXIRI联合贝伐单抗方案加用阿特珠单抗的耐药性:AtezoTRIBE研究的二次分析

Antoniotti, C; Carullo, M; Rossini, D; Pietrantonio, F; Salvatore, L; Lonardi, S; Tamberi, S; Sciortino, C; Conca, V; Calegari, M A; Ciracì, P; Tamburini, E; Bergamo, F; Boccaccio, C; Passardi, A; Ritorto, G; Ugolini, C; Aprile, G; Galon, J; Cremolini, C

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

接受呋喹替尼联合最佳支持治疗的转移性结直肠癌患者的质量调整生存期:FRESCO-2 研究结果

Stintzing, S; Tabernero, J; Satoh, T; Dasari, A; Lonardi, S; Eng, C; Garcia-Carbonero, R; Elez, E; Yoshino, T; Sobrero, A F; Yao, J C; Kasper, S; Arnold, D; Basic, E; Granold, M; Petschulies, M; Wu, L; Chung, Y-C; Chen, L; Yang, Z; Van Cutsem, E

Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis

肿瘤和淋巴结分期对III期结肠癌患者辅助奥沙利铂化疗疗效的影响:一项ACCENT汇总分析

Cohen, R; Raeisi, M; Chibaudel, B; Yothers, G; Goldberg, R M; Bachet, J-B; Wolmark, N; Yoshino, T; Schmoll, H-J; Haller, D G; Kerr, R; Lonardi, S; George, T J; Shacham-Shmueli, E; Shi, Q; André, T; de Gramont, A

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial

通过液体活检进行全面的基因组分析,可以描绘转移性结直肠癌的突变图谱,从而预测 CAPRI-2 GOIM 试验中 FOLFIRI 联合西妥昔单抗的抗肿瘤疗效。

Ciardiello, D; Boscolo Bielo, L; Napolitano, S; Latiano, T P; De Stefano, A; Tamburini, E; Toma, I; Bordonaro, R; Russo, A E; Pisconti, S; Nisi, C; Lotesoriere, C; Vallarelli, S; Lonardi, S; Iacono, D; Cremolini, C; Tortora, G; Tagliaferri, P; Pietrantonio, F; Rosati, G; Lucenti, A; Scartozzi, M; Brunetti, O; Cinieri, S; Zampino, M G; Zaniboni, A; Berardi, R; Paoletti, G; Febbraro, A; Martinelli, E; Troiani, T; Cioli, E; Normanno, N; Di Maio, M; Parente, P; Fazio, N; Curigliano, G; De Vita, F; Avallone, A; Maiello, E; Ciardiello, F; Martini, G

Claudin 18.2: a promising actionable target in biliary tract cancers

Claudin 18.2:胆道癌中一个有前景的可靶向治疗靶点

Angerilli, V; Sacchi, D; Rizzato, M; Gasparello, J; Ceccon, C; Sabbadin, M; Niero, M; Bergamo, F; Cillo, U; Franzina, C; Luchini, C; Dei Tos, A P; Lonardi, S; Fassan, M

Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative

在欧洲推广针对胃肠道癌症的大型跨国学术临床试验:ENGIC(欧洲胃肠道癌症网络)倡议

Taieb, J; Seligmann, J; Modest, D; Girault, C; Rivera, F; Mahillo, E; Osterlund, P; Pfeiffer, P; Malka, D; Louvet, C; Siebenhuner, A R; Morf, C; de la Fouchardiere, C; Monard, L; Koopman, M; Vink, G; Borbath, I; Dewever, L; Adams, R; Reinacher-Schick, A; Pietrantonio, F; Lonardi, S; Aparicio, T; Cremolini, C